EE15 Cost-Effectiveness Analysis of Oral Semaglutide as the Second-Line and Third-Line Treatment for Type 2 Diabetes Patient
Abstract
Authors
E.C.H. Tan M.C. Yang
E.C.H. Tan M.C. Yang
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now